← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $624B	2,122	+133	+7%	$193B
2	2 Pfizer PFE $169B	1,861	+118	+7%	$138B
3	3 Merck MRK $372B	1,723	+104	+6%	$121B
4	4 AbbVie ABBV $510B	1,606	+103	+7%	$73.5B
5	5 Gilead Sciences GILD $197B	1,441	+112	+8%	$119B
6	6 Bristol-Myers Squibb BMY $125B	1,411	+108	+8%	$70.9B
7	7 Amgen AMGN $238B	1,341	+118	+10%	$98.5B
8	8 Novartis NVS $288B	919	+44	+5%	$22B
9	9 GSK GSK $99.2B	729	+27	+4%	$10.9B
10	10 Regeneron Pharmaceuticals REGN $83.1B	512	+38	+8%	$29.6B
11	11 AstraZeneca AZN $261B	404	+2	+0.5%	$6.57B
12	12 Jazz Pharmaceuticals JAZZ $14B	358	+32	+10%	$8.93B
13	13 Incyte INCY $23.1B	284	+64	+29%	$12B
14	14 Myriad Genetics MYGN $415M	273	-3	-1%	$3.25B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	214	+20	+10%	$4.14B
16	16 DELISTED Exact Sciences EXAS	198	+23	+13%	$2.31B
17	17 Puma Biotechnology PBYI $545M	189	+5	+3%	$5.14B
18	18 Opko Health OPK $1.19B	176	-7	-4%	$780M
19	19 DELISTED Assertio ASRT	168	+9	+6%	$860M
20	CLVS 20 DELISTED Clovis Oncology, Inc. CLVS	143	+5	+4%	$1.86B
21	INFI 21 DELISTED Infinity Pharmaceuticals, Inc. INFI	143	+25	+21%	$779M
22	22 DELISTED Merrimack Pharmaceuticals, Inc. MACK	143	+11	+8%	$657M
23	SPPI 23 DELISTED Spectrum Pharmaceuticals Inc SPPI	137	+10	+8%	$329M
24	24 Halozyme HALO $13.8B	132	+11	+9%	$883M
25	25 DELISTED Immunogen Inc IMGN	131	-10	-7%	$423M